FDA's Woodcock On Obesity Drugs: It's Hard To Fight Mother Nature
Executive Summary
FDA officials remain skeptical that a drug can be developed to treat morbid obesity and have acceptable side effects
You may also be interested in...
Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Cmte On CV Risk
Orexigen halts Contrave development for U.S., but the firm will appeal the division's "unprecedented" trial request through FDA's dispute resolution process.
Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Committee On CV Risk
FDA will conduct an advisory committee early in 2012 to discuss how to assess the cardiovascular risk of weight-loss drugs, Orexigen revealed June 3 in announcing the firm will halt development in the U.S. of its obesity medication Contrave.
Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Committee On CV Risk
FDA will conduct an advisory committee early in 2012 to discuss how to assess the cardiovascular risk of weight-loss drugs, Orexigen revealed June 3 in announcing the firm will halt development in the U.S. of its obesity medication Contrave.